{
  "trial_id": "NCT03250910",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age > or = 20 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Chronic HCV infection, defined as detectable HCV antibody (anti-HCV; Abbott HCV EIA 2.0, Abbott Laboratories, Abbott Park, Illinois, USA) and quantifiable serum HCV RNA (Cobas TaqMan HCV Test v2.0, Roche Diagnostics GmbH, Mannheim, Germany, lower limit of quantification [LLOQ]: 25 IU/mL) for \u2265 6 months",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Chronic kidney disease (CKD) stage \u2265 4,",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Organ transplantation",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Prior DAA exposure",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Refusal to provide written informed consent.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV. He is on IFN, RBV and direct antiviral drugs for the past 6 months.",
  "_meta": {
    "topic_id": "64",
    "trial_id": "NCT03250910",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}